Financials Trevena, Inc.

Equities

TRVN

US89532E2081

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-06-07 pm EDT 5-day change 1st Jan Change
0.3996 USD -1.16% Intraday chart for Trevena, Inc. +2.46% -44.66%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 77.86 336 95.83 11.03 10.96 7.415 - -
Enterprise Value (EV) 1 77.86 336 95.83 11.03 10.96 7.415 7.415 7.415
P/E ratio -3.11 x -9.3 x -1.82 x -0.19 x -0.23 x -0.28 x -0.3 x -0.41 x
Yield - - - - - - - -
Capitalization / Revenue 2,512 x 109 x 169 x -26.4 x 3.51 x 742 x 0.83 x -
EV / Revenue 2,512 x 109 x 169 x -26.4 x 3.51 x 742 x 0.83 x -
EV / EBITDA - -11,584,535 x - - - - - -
EV / FCF - - - - - - - -
FCF Yield - - - - - - - -
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 3,704 6,281 6,581 7,714 15,174 18,341 - -
Reference price 2 21.02 53.50 14.56 1.430 0.7221 0.4043 0.4043 0.4043
Announcement Date 3/12/20 3/9/21 3/31/22 3/30/23 4/1/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 0.031 3.069 0.567 -0.418 3.125 0.01 8.95 -
EBITDA - -29.01 - - - - - -
EBIT 1 -26.58 -29.48 -51.92 -56.38 -35.29 -32.75 -26.59 -34.08
Operating Margin -85,741.94% -960.74% -9,157.85% 13,486.84% -1,129.22% -327,530% -297.07% -
Earnings before Tax (EBT) 1 -24.87 -29.07 -51.59 -53.67 -40.29 -29.09 -24.5 -31.81
Net income 1 -24.87 -29.37 -51.59 -53.67 -40.29 -32.09 -24.85 -31.81
Net margin -80,229.03% -956.96% -9,098.41% 12,839.71% -1,289.25% -320,945% -277.63% -
EPS 2 -6.750 -5.750 -8.000 -7.590 -3.160 -1.465 -1.365 -0.9900
Free Cash Flow - - - - - - - -
FCF margin - - - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 3/12/20 3/9/21 3/31/22 3/30/23 4/1/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 -0.001 0.02 - -0.438 - 0.006 3.021 0.18 -0.082 0.02 - - -
EBITDA - - - - - - - - - - - - -
EBIT 1 -14.03 -16.46 -14.81 -15.76 -9.347 -10.12 - - -10.15 - -7.902 -7.553 -7.42
Operating Margin 1,403,300% -82,300% - 3,597.03% - -168,650% - - 12,374.39% - - - -
Earnings before Tax (EBT) 1 -13.95 -16.39 -14.98 -15.3 -7.005 -7.818 - - -16.53 - -7.423 -7.065 -6.922
Net income 1 -13.95 -16.39 -15.04 -15.3 -7.005 -7.818 - - -16.53 - -7.423 -7.065 -6.922
Net margin 1,395,300% -81,945% - 3,492.01% - -130,300% - - 20,156.1% - - - -
EPS 2 -2.000 -2.500 -2.250 -2.250 -0.7300 -0.8100 -0.6900 -0.5700 -1.130 -0.3600 -0.4050 -0.3500 -0.3500
Dividend per Share - - - - - - - - - - - - -
Announcement Date 3/31/22 5/11/22 8/11/22 11/9/22 3/30/23 5/15/23 8/14/23 11/14/23 4/1/24 5/15/24 - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow - - - - - - - -
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex - - 0.02 0.03 - - - -
Capex / Sales - - 2.82% -6.7% - - - -
Announcement Date 3/12/20 3/9/21 3/31/22 3/30/23 4/1/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.4043 USD
Average target price
4 USD
Spread / Average Target
+889.36%
Consensus
  1. Stock Market
  2. Equities
  3. TRVN Stock
  4. Financials Trevena, Inc.